Results 161 to 170 of about 43,170 (263)

Hospitalisation Is a Strong Risk Factor for Discontinuation of Sodium‐Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10210-10217, November 2026.
ABSTRACT Aims Sodium–glucose cotransporter 2 inhibitors (SGLT2i) are commonly withheld during hospitalisation because of concerns about diabetic ketoacidosis. We examined whether hospitalisation was associated with discontinuation of SGLT2i and compared patterns with another anti‐hyperglycaemic medicine without similar inpatient safety concerns ...
Tamara Y. Milder   +13 more
wiley   +1 more source

Association of Lipid Ratios With Cardiovascular Outcomes in Type 2 Diabetes: A Population Cohort Study

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10236-10247, November 2026.
ABSTRACT Aims To identify low‐ and high‐risk intervals for major adverse cardiovascular events (MACE) and all‐cause mortality according to lipid ratios in adults with Type 2 diabetes mellitus (T2DM), stratified by sex. Materials and Methods We used primary care electronic health records from the Spanish National Health Service including 303 199 adults ...
Enrique Carretero‐Anibarro   +5 more
wiley   +1 more source

Integrative pan-cancer analysis of dipeptidyl peptidase 4 with clinical and <i>in vitro</i> validation in prostate cancer. [PDF]

open access: yesFront Immunol
Li Y   +10 more
europepmc   +1 more source

Person‐Reported and Continuous Glucose Monitoring (CGM) Recorded Hypoglycaemia in People With Insulin‐Treated Type 2 Diabetes and Mild to Moderate Chronic Kidney Disease; Post Hoc Analysis From the Hypo‐METRICS Study

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10664-10669, November 2026.
ABSTRACT Background and Aims People with diabetes and chronic kidney disease (CKD) may be at increased risk of iatrogenic hypoglycaemia. We compared rates of sensor‐detected (SDH) and person‐reported hypoglycaemia (PRH) in people with insulin‐treated Type 2 diabetes (T2D) with and without CKD in the Hypo‐METRICS study.
Julie M. B. Brøsen   +39 more
wiley   +1 more source

Initiation of SGLT2 Inhibitors Versus DPP‐4 Inhibitors in Metformin Users and Risk of Incident Depression: A Nationwide, Claims‐Based Active‐Comparator New‐User Study

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10765-10779, November 2026.
ABSTRACT Aims To examine the association between initiation of sodium‐glucose cotransporter‐2 (SGLT2) inhibitors and risk of incident depression compared with dipeptidyl peptidase‐4 (DPP‐4) inhibitors among adults with newly diagnosed Type 2 diabetes receiving metformin.
Sangwoo Park   +5 more
wiley   +1 more source

Cardiorenal Mortality and Safety Outcomes of GLP‐1 Receptor Agonists in Type 2 Diabetes With BMI Below 27 kg/m2: A Target Trial Emulation

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10498-10512, November 2026.
ABSTRACT Aims Cardiorenal evidence for glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) derives mainly from trials in overweight or obesity; data in adults with Type 2 diabetes (T2D) and body mass index (BMI) below 27 kg/m2 are limited. Materials and Methods We emulated a target trial in the TriNetX US Collaborative Network (index dates 2020 to ...
Shao‐Chia Chen   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy